Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab for MRD-positive ALL
NCT02767934Phase 2Terminated
- Sponsor
- University of Washington
- Start
- Jan 2017
- Primary completion
- Jul 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in acute lymphoblastic leukemia (ALL), sponsored by University of Washington. Started Jan 2017; status: terminated.
02
Drugs
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT02767934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02767934.